Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

about

The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC-Trial): A randomized controlled first-in-human trial.Creatine kinase, energy reserve, and hypertension: from bench to bedside

P2860

Q46801982-7030DD84-5FB7-47E9-B838-EF056CD06A6A Q58804822-90ACADDC-F4C6-49B9-BCA3-81F5CC96784D

P2860

Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Item

http://www.wikidata.org/entity/Q38763352

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Drug Development for Hypertens ...... nt for Resistant Hypertension?

@en

type

Item

label

Drug Development for Hypertens ...... nt for Resistant Hypertension?

@en

prefLabel

Drug Development for Hypertens ...... nt for Resistant Hypertension?

@en

P1476

Drug Development for Hypertens ...... nt for Resistant Hypertension?

@en

P2093

David A Calhoun

http://www.w3.org/2001/XMLSchema#string

Eduardo Pimenta

http://www.w3.org/2001/XMLSchema#string

P2860

Projections of global mortality and burden of disease from 2002 to 2030

Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association

A controlled trial of renal denervation for resistant hypertension

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Apparent and true resistant hypertension: definition, prevalence and outcomes

Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.

Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort

Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Trends in risks associated with new drug development: success rates for investigational drugs.

P2888

s11906-016-0634-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11906-016-0634-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1042717391

http://www.w3.org/2001/XMLSchema#string

P698

26949263

http://www.w3.org/2001/XMLSchema#string

Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

about

P2860

P2860

Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698